Effect of Rowachol on the Gallbladder Dysmotility Disorder Based on Gallbladder Ejection Fraction

Area of Science:

• Gastroenterology
• Hepatology
• Pharmacology

Background:

• Laparoscopic cholecystectomy is standard for biliary pain, but medical treatments are less studied.
• Rowachol, a choleretic agent, comprises six cyclic monoterpenes.
• Typical biliary pain can occur with or without gallstones.

Purpose of the Study:

• To investigate clinical improvement in patients with typical biliary pain treated with Rowachol.
• To assess changes in gallbladder ejection fraction (GBEF) following Rowachol therapy.

Main Methods:

• Retrospective review of 138 patients with typical biliary pain undergoing cholescintigraphy.
• Inclusion of 31 patients receiving Rowachol for >2 months with follow-up GBEF measurements.
• Analysis of pre- and post-treatment symptoms and GBEF using fatty meal-stimulated cholescintigraphy.

Main Results:

• Symptom resolution in 67.7% of patients after a median 10-month Rowachol treatment.
• Significant improvement in mean GBEF post-treatment (42.6% to 53.0%, p=0.012).
• Marked GBEF increase in patients with initial GBEF ≤35% (21.3% to 49.1%, p=0.008).

Conclusions:

• Rowachol demonstrates potential benefits for improving gallbladder dysfunction.
• The agent may enhance treatment response in patients experiencing typical biliary pain.
• Rowachol offers a viable medical treatment option for gallbladder issues.